Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single ascending dose study of RO5545965 in healthy volunteers
NL-OMON36943Phase 1Active, not recruiting
- Sponsor
- Roche
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Schizophrenia Spectrum Disorders (SSD) and schizophrenia comparing RO5545965 with Placebo (2 arms). Primary endpoints: Prolactin, Plasma drug concentrations and 10 more. Started Oct 2012; status: active, not recruiting.
02
Drugs
RO5545965
03
Conditions
Schizophrenia Spectrum Disorders (SSD)schizophrenia
Beyond the preview
Go deeper on NL-OMON36943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36943.